Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Plus Bevacizumab in Relapsed SCLC
NCT00317200Phase 2Completed
- Sponsor
- Hoosier Cancer Research Network
- Start
- Apr 2006
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in small cell lung cancer (SCLC), sponsored by Hoosier Cancer Research Network. Primary endpoint: Progression Free Survival at 18 months. Started Apr 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00317200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317200.